Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The anti-malarial agent dihydroartemisinin (DHA) has strong anti-angiogenic activity. This study aimed to investigate the molecular mechanism underlying this effect of DHA on angiogenesis. We found that DHA shows a dose-dependent inhibition of proliferation and migration of in HUVECs. DHA specifically down-regulates the mRNA and protein expression of VEGFR2 in endothelial cells. Treatment with DHA increases IκB-α protein and blocks nuclear translocation of NF-κB p65. In addition, DHA directly regulates VEGFR2 promoter activity through p65 binding motif, and decreases the binding activity of p65 and VEGFR2 promoter, suggesting defective NF-κB signaling may underlie the observed effects of DHA on VEGFR2 expression. In the presence of the NF-κB inhibitor PDTC, DHA could not further repress VEGFR2. Co-treatment with PDTC and DHA produced minimal changes compared to the effects of either drug alone in in vitro angiogenesis assays. Similar findings were found in vivo through a mouse retinal neovascularization model examining the effects of PDTC and DHA. Our data suggested that DHA inhibits angiogenesis largely through repression of the NF-κB pathway. DHA is well tolerated, and therefore may be an ideal candidate to use clinically as an angiogenesis inhibitor for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 3×
“We concluded 1480 Volume 15 Issue 11Cancer Biology & Therapy that DHA specifically inhibits VEGFR2 expression, the RTK that mediates the pro-angiogenic effect of VEGF.”
BackgroundInfluentialAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“Therefore, angiogenesis inhibitors could be clinically useful for the treatment of cancer as well as other diseases dependent on new blood vessel formation.(3,4) A number of growth factors have been implicated in the control of angiogenesis but vascular endothelial growth factor (VEGF) is a major regulator of angiogen…”
BackgroundEndothelial cells and VEGF in vascular development
Coultas, L., Chawengsaksophak, K., & Rossant, J. (2005) · Nature · doi:10.1038/nature04479 · Cited by 1,016 · cited 1×
“A number of growth factors have been implicated in the control of angiogenesis but vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis in a variety of physiological and pathological processes.(5,6) VEGF binds to 2 major receptor tyrosine kinases, VEGFR1 (fms-like tyrosine kinase, Flt-1) and…”
BackgroundAnimal models of choroidal and retinal neovascularization
Grossniklaus, H. E., Kang, S. J., & Berglin, L. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.05.003 · Cited by 350 · cited 1×
“The model of ischemiainduced retinal neovascularization that we utilized is a wellaccepted in vivo angiogenesis model.(50) To our knowledge this is the first study demonstrating that DHA significantly inhibits retinal neovascularization.”
MethodBrouard, S., Berberat, P. O., Tobiasch, E., Seldon, M. P., Bach, F. H., & Soares, M. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108317200 · Cited by 306
Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway
Wang, S.-J., Sun, B., Cheng, Z.-X., Zhou, H.-X., Gao, Y., Kong, R., Chen, H., Jiang, H.-C., Pan, S.-H., Xue, D.-B., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1643-7 · Cited by 86 · cited 2×
“Previously it has been shown that DHA can prevent the degradation of IkB-a protein in cancer cell lines.(26,36) The current study demonstrates that DHA also increases IkB-a protein in endothelial cells, and blocks translocation of p65 into the nucleus.”
BackgroundMethod
Cited by
From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy
Efferth, T. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.009 · Cited by 632
Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine
Luo, H., Vong, C. T., Chen, H., Gao, Y., Lyu, P., Qiu, L., Zhao, M., Liu, Q., Cheng, Z., Zou, J., et al. (2019) · Chinese Medicine · doi:10.1186/s13020-019-0270-9 · Cited by 563
NF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
Differential sex-specific effects of oxygen toxicity in human umbilical vein endothelial cells
Zhang, Y., & Lingappan, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.058 · Cited by 35
Liu, F., Liu, J., Xiang, H., Sun, Z., Li, Y., Li, X., Liu, Y., & Liu, J. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13683 · Cited by 9
Self-citation
Metadata
- Authors
- Dong, F., Zhou, X., Li, C., Yan, S., Deng, X., Cao, Z., Li, L., Tang, B., Allen, T. D., & Liu, J.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2014-11-02
- Volume
- 15
- Issue
- 11
- Pages
- 1479-1488
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2032576041
- Cited by
- 85
- References
- 6
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis. https://app.cochat.ai/papers/10.4161/15384047.2014.955728
- The paper
- Dong, F., Zhou, X., Li, C., Yan, S., Deng, X., Cao, Z., Li, L., Tang, B., Allen, T. D., & Liu, J. (2014). Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis. Cancer Biology & Therapy. https://doi.org/10.4161/15384047.2014.955728
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.